CPA Conference Final Day: On China, Rubio And Posey Go Hard
Three members of Congress representing both parties are writing legislation to help domestic enterprises post-pandemic.
CPA Conference Day 1: Making Generic Pharmaceuticals A National Security Imperative
Healthcare panelist and Phlow CEO Eric Edwards on what needs to be done to make more pharmaceutical drugs here. Most of them are coming in from Europe, India and…increasingly…China.
What About A ‘Country of Origin’ Label for Pharmaceuticals?
By Kenneth Rapoza, CPA Industry Analyst The FDA hasn’t inspected nearly 1,000 overseas labs making drugs for the US market due to the pandemic. But
America’s Dependence on China for Essential Medicines a Growing Safety Threat
Rosemary Gibson chairs the healthcare committee of the Coalition for a Prosperous America. She is the author of “China Rx: Exposing the Risks of America’s
FDA Releases Massive List of Essential Medicines That Should Be Made In USA
By Kenneth Rapoza, CPA Industry Analyst Score one for the local pharmaceutical industry. FDA’s essential medicine and critical inputs list gives domestic producers a a
Heparin Shortages Due to a Dependence on China. Why American Cattle is the Solution.
By Kenneth Rapoza, CPA Industry Analyst Why are we dependent on China’s pig population for a critical animal source material used in making heparin? Bovine
The U.S. needs to support American-made medicines
CPA’s Take: CivicaRX CEO Martin VanTrieste explains why it is essential, and achievable to reshore pharmaceutical production to the US. Two years ago, a group
Industry Analysis: Securing USA Made PPE Before the Next Health Crisis
By Kenneth Rapoza, CPA Industry Analyst Summary: If we experience a global pandemic like this again, we know two things to be true: we can’t
Reshoring Pharmaceutical Production: Are Buy America Laws Enough?
By Kenneth Rapoza, Industry Analyst, CPA President Trump and many members of Congress are talking about reshoring pharmaceutical production. We look at the benefits of
Domestic Drug Producers Score A Win With Executive Order
By Ken Rapoza, CPA Industry Analyst Major pharmaceutical importers have pushed back against the White House’s proposal to support domestic labs. But on Thursday, American
